Table of Contents
Print

Can genes explain why some people do not respond to ADHD meds? 

Yes, ADHD non-response genetics may help explain why certain individuals don’t benefit from typical ADHD treatments. While stimulant medications like methylphenidate and amphetamines work well for many, a significant number of people experience limited benefits or troublesome side effects. This variability in treatment resistance may, in part, be down to genetic differences. 

Why does treatment not work the same for everyone 

This is because multiple biological, psychological, and environmental factors influence an individual’s response. 

Genetic variability in drug targets  

Genes such as DRD4, DAT1 (SLC6A3), and COMT affect how dopamine is processed in the brain, a key pathway for most ADHD medications. Certain variants may blunt a drug’s effectiveness by altering how dopamine receptors or transporters respond. 

Pharmacokinetics: how your body processes drugs  

Genes like CYP2D6 (for atomoxetine) and CES1 (for methylphenidate) influence how quickly or slowly a drug breaks down. If you metabolise a medication too quickly, it might not stay active long enough to help and side effects may appear before benefits do. 

Polygenic effects and cumulative risk  

Often, it is not one gene but many working together. People with a high burden of genetic variants linked to ADHD but a low number of variants linked to drug response may be more likely to experience non-response. This is an area of active pharmacogenetic research. 

What this means for ADHD care 

  • Genetic insights won’t always offer a clear answer, but they can help inform more tailored approaches, especially when someone has tried multiple medications without success. 
  • In future, we may use pharmacogenetic testing to guide first-line treatment choices, reducing the need for trial and error. 

Visit providers like ADHD Certify for personal consultations that explore genetic factors behind treatment resistance.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc, author for my patient advice - mypatientadvice.co.uk

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Rebecca Fernandez, MBBS, author and a reviewer for my patient advice - mypatientadvice.co.uk

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.